RT @DrCassySims: Does Bimekizumab, anti-IL17F, work in PsA? #ACR22 @RheumNow Abstract #L02 ðPhase 3, randomized, p
Tweet Content
Does Bimekizumab, anti-IL17F, work in PsA? #ACR22 @RheumNow
Abstract #L02
💊Phase 3, randomized, placebo-controlled study
💉Biologic naive patients
✋ Week 52: 53-54% BKZ groups achieved ACR502 (v. 50% in TNFi)
📍benefits sustained to week 52
🛑No new safety signals
Show on Archive Page
On
Display in Search Results
On
PDQ
Off